Lexogen and Bluebee partner to bring the SLAMseq metabolic RNA sequencing data analysis pipeline to the users

Rijswijk, The Netherlands and Vienna, Austria: 10 November 2017 - Bluebee, a company driving genomic data-driven medicine, and Lexogen a company enabling the analysis of the complete transcriptome, announce the successful integration of the SLAMdunk pipeline on Bluebee's private cloud-based platform, making it available to analyze data generated by every user of the SLAMseq Metabolic RNA Labeling Kit from Lexogen.

The family of SLAMseq Metabolic RNA labeling kits was successfully released in September this year accompanying the publication of the SLAMseq method in the Nature Methods journal (DOI:10.1038/nmeth.4435). The method is based on S4U labeling of RNA in cell cultures, alkylation of RNA with iodoacetamide, and consequent introduction of T to C mutations in cDNA. By just adding two extra steps to RNA-Seq workflows, the SLAMseq approach provides a unique tool for the study of RNA metabolism and measure nascent RNA expression. Synthesis and degradation can be monitored transcriptome-wide by analyzing nascent and steady-state RNA levels in the same cell extract.

More info on Bluebee's website


Next > Kees Verhaar appointed as Chairman of Avantium’s Supervisory Board

Previous > Nexstim raises € 1.75 million via a directed issue of new shares to London-based investor City Financial - Funds to be used to support beginning the commercialisation of its NBT® system